Maze Therapeutics, Inc.
MAZE
$13.71
$0.403.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.50M | 167.50M | 167.50M | 167.50M | 165.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.50M | 167.50M | 167.50M | 167.50M | 165.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.50M | 167.50M | 167.50M | 167.50M | 165.00M |
| SG&A Expenses | 30.57M | 28.10M | 26.42M | 25.91M | 24.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.33M | 117.30M | 109.91M | 103.24M | 101.74M |
| Operating Income | -125.83M | 50.20M | 57.59M | 64.26M | 63.26M |
| Income Before Tax | -121.35M | 53.11M | 53.40M | 56.68M | 56.96M |
| Income Tax Expenses | -554.00K | 1.17M | 1.17M | 1.45M | 1.73M |
| Earnings from Continuing Operations | -120.80 | 51.94 | 52.23 | 55.23 | 55.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.80M | 51.94M | 52.23M | 55.23M | 55.24M |
| EBIT | -125.83M | 50.20M | 57.59M | 64.26M | 63.26M |
| EBITDA | -123.00M | 53.23M | 60.88M | 67.83M | 67.05M |
| EPS Basic | -4.93 | 1.76 | 1.45 | -8.02 | -17.72 |
| Normalized Basic EPS | -14.21 | 23.04 | 16.34 | 17.45 | 16.52 |
| EPS Diluted | -5.23 | -1.24 | -1.58 | -10.75 | -20.46 |
| Normalized Diluted EPS | -14.21 | 6.64 | -0.07 | 1.04 | 0.11 |
| Average Basic Shares Outstanding | 77.29M | 35.88M | 9.59M | 9.47M | 9.35M |
| Average Diluted Shares Outstanding | 77.29M | 37.80M | 11.51M | 11.39M | 11.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |